Introduction {#s1}
============

Lymphocytes are a common component of the leukocyte infiltrates found in irradiated tissues both during acute and chronic phases (Hong et al., [@B29]; Chiang et al., [@B16]; Fajardo, [@B22]; Yoshii, [@B101]; Moravan et al., [@B56]), and in humans and other species (Teymoortash et al., [@B86]; Toma et al., [@B88]). While some pathologists insist that they are unimportant as a [cause]{.ul} of radiation-induced damage (Fajardo, [@B22]), many consider them as contributing to radiation-induced symptoms and pathogenesis. Strangely, both may be right! However, many lymphocytes in irradiated lesions seem activated rather than innocently trapped and since activated lymphocytes function as effector cells and/or as managing directors of bystander non-immune and immune cells through the release of effector cytokines, it is hard to ignore their significance. In this sense, acute and late radiation effects can be considered as acute and chronic inflammatory diseases. Placing lymphocytes in the correct framework to understand their possible roles; however, requires understanding of immune recognition of "self" and how responses are controlled by allocating immune functions to different T cell subsets and this will be the focus of this review, with the understanding that other lymphocyte subsets are present and may also be important.

The need to transplant tissues to help casualties during the Second World War foundered on what Medawar called the "uniqueness of the individual." The phenomenon of transplant rejection, however, fostered important immunological theories based on recognition of "self"/"non-self." Consensus grew for antigen-driven selection and expansion of responsive lymphocyte clones that developed so as to express a single specificity. Positive and negative selection processes during development were postulated to shape the immune repertoire so as to eliminate the chance of autoimmunity. These theories have generally stood the test of time. T cell repertoires are shaped in the thymus by positive selection of naive T cell clones with T cell receptors (TCR) that have moderate affinity for self MHC antigens and that later develop into effector T cells recognizing peptide antigen in peripheral lymphoid organs in the context of MHC class I (CD8+ cells) or class II (CD4+ cells). Negative selection allows those with low affinity receptors for MHC+self to move on while those with high affinity for "self" get deleted, probably by more than one mechanism (central tolerance). These selection processes are, however, far from complete and the concepts have had to be modified to invoke mechanisms to maintain tolerance when it became clear that anti-self reactivity was still possible (peripheral tolerance). This is largely the purview of Tregs, whose absence causes severe autoimmune disease, excessive lymphoid proliferation, and immune destruction that is basically incompatible with life. Tregs (formally known as suppressor T cells) are the major players in preventing excessive damage to self (Peterson, [@B66]), and there is every reason to assume that they play important roles in radiation-induced tissue damage.

T cell subsets
==============

CD4+ naïve T cells have the capacity to differentiate along different paths so as to effect distinct functions following antigenic stimulation largely through elaboration of distinct cytokine profiles. Initially, mutually exclusive Th1 and Th2 subsets helped explain why cellular immunity (Th1-mediated) could exist in the absence of antibody production (Th2-mediated) and vice-versa. More recently, the Th17 subset, which is a potent inducer of tissue inflammation and has been associated with the pathogenesis of many autoimmune diseases, has emerged, as have adaptive or induced Tregs (iTregs) that share participation of TGF-β in their differentiation. Also, a Tfh subset of follicular helper cells assists B cells in antibody production. All these "classic" T cells become effector cells by engagement of TCRs containing α and β chains (signal 1) and of co-stimulatory molecules (signal 2) expressed by mature antigen presenting cells, which requires specific cytokines produced primarily by innate immune cells that recognize molecules in a pathological site through pattern recognition receptors (PRRs). Dendritic antigen presenting cells (DC) appear to be the major drivers of these responses, but there are others. Each T cell subset has distinct transcription factors controlling their functionality and they often appear to operate in a reciprocal fashion. One way this can occur is through interconversion for example of iTregs into Th17 by IL-6. Th1 and Th2 subsets are less flexible though they often appear to be in opposition. The factors that drive specific T cell subsets are the keys that unlock the enormous therapeutic of the immune system.

In addition to these adaptive T cell subsets, natural subsets of regulatory cells (nTregs), γδT cells, and natural killer T (NKT) cells emerge from the thymus ready for action and bridge innate and adaptive immunity. nTregs, like iTregs are controlled by the Foxp3 transcription factor. They produce immunosuppressive cytokines like TGF-β and IL-10 and both have TCRs that focus on "self" antigens. Cells bearing TCRs composed of γ and δ chains mostly lack CD4 and CD8 expression and are not MHC restricted. They respond primarily to small non-peptide phosphoantigens, which are metabolites of isoprenoid biosynthesis pathways. While they are found in blood, they form a more major component of the intra-epithelial lymphocyte pool. They are able to produce Th1-type cytokines like IFN-γ and TNF-α and may be a major innate source of IL-17. The exact distinctions between γ δT cells, Th1/Th17, and nTh17 cells that are reported in the literature are not yet clear. γ δT cells, however, form a first line of defense against Mycobacteria and Candida, as well as being involved in anti-tumor responses and autoimmunity. They have been found to accumulate around blood vessels and mucosal airways in macaques that have inhaled *Yersinia pestis* (Huang et al., [@B32]), where they release the homeostatic cytokine FGF-7. This is reminiscent of perivascular cuffs of lymphocytes often seen in radiation-damaged tissues. NKT cells, in contrast, express an invariant and limited TCR that recognizes lipid antigens presented in the context of CD1d. They play diverse roles in enhancing some forms of cell-mediate immunity while being more suppressive toward autoimmune responses.

The prelude to the adaptive T cell overture involves more than just innate T cells. Ionizing radiation like other insults damages tissues, and damaged tissues show and tell various "danger" signals including Damage-Associated Molecular Pattern molecules (DAMPs) to the immune system (Matzinger, [@B50]; Shi et al., [@B83]; Lotze et al., [@B43]; Curtin et al., [@B20]; Sato et al., [@B77]; Kawai and Akira, [@B37]). DAMPs can be secreted and/or released into extracellular spaces prior to cell death but the most dramatic surge follows cell death with the release of HMGB1, dsDNA, chromatin, RNA, mitochondria, etc. It may be significant that the conformation of intracellular molecules may change when they are in an extracellular space with oxidation making such moieties a particularly interesting source of radiation DAMPs (Miller et al., [@B55]). Once released, DAMPs bind to PPRs and initiate signaling cascades and communications between immune cells through activation of cytokine and chemokine networks so as hopefully to eliminate danger and restore homeostasis, leading to regeneration and healing of tissues (Schaue and McBride, [@B78]; Schaue et al., [@B79]). This process is characterized by infiltration of various host cells into the site---a textbook inflammatory response---initially polymorphs and monocytes and slightly later lymphocytes. Alterations in cellular subsets and functions with time aim to turn the pro-inflammatory, pro-oxidant environment into one that is more compatible with tissue restoration and rescue. In the case of radiation-damaged mucosal surfaces, various DAMPs may actually work in cohort with microbes to generate inflammatory infiltrates and activate innate immune defenses (Abreu et al., [@B1]). A critical issue is whether the irradiated microenvironment is sufficient to mature DCs into competent antigen presenting cells that can activate adaptive T cell responses (Banchereau and Steinman, [@B5]; Gallucci et al., [@B23]). In other words, DAMPs initiate signaling cascades in DCs that drives them to not only present the antigen to T cells (signal 1) but simultaneously to mature and to show co-stimulatory molecules (signal 2), both of which are needed to kick off a full-blown immune response. Conversely, antigen-presentation in the absence of danger leads to a muted or anergic response as T cells have been taught to ignore or are switched off by any antigen that is not shown in the right context (Steinman et al., [@B84]).

The important concept that emerges is that "danger" tunes-up the immune system to proceed in more orderly progressions to develop a symphony involving multiple elements with feedback through chemokine and cytokine control loops that amplify and reiterate themes until final resolution. Adaptive immune effector T cells play major roles in perpetuating damaging processes while Tregs and other suppressor cells calm the situation and try to bring resolution. As a result, examination of an immune reaction site may show a predominance of a particular T cell subset and associated cytokine profile at any one time, but at least some of the rest of the orchestra will inevitably be present with the relative contributions varying with time. Perhaps the most surprising and exciting discovery in recent years is that the volume and the nature of the response is under tight control primarily by Treg cells and that their removal uncovers an immune system that is able to participate in multiple forms of autoimmune responses, indicating the extent to which central tolerance is limited as a mechanism for controlling autoimmunity. The corollary is that the immune system is in "lock down" mode under most normal circumstances and the generation of an effector response requires local removal of restrictions. These concepts are highly relevant for consideration of the role of T cells in radiation-induced normal tissue responses, just as they are for immune recognition of tumors during radiation therapy.

Signs of autoimmunity after tissue irradiation
==============================================

Damage to tissues following irradiation is a result of direct cell kill plus collateral or bystander damage caused by vasculature damage and inflammatory infiltrates. Initially, changes in redox in the irradiated normal tissue microenvironment play a role in preparing it for immune recognition and activation. This involves decorating it with recognition molecules and release of chemokines and chemokines and receptors that attract different inflammatory subsets cells (Lorimore et al., [@B42]; Lugade et al., [@B44], [@B45]; Matsumura et al., [@B49]; Burnette et al., [@B13]). We, and many others, have shown that irradiation increases expression of MHC class I and II molecules, co-stimulatory molecules, chemokine receptors, and other cell surface markers (Santin et al., [@B76]; Morel et al., [@B57]; Seo et al., [@B80]; Garnett et al., [@B24]; Reits et al., [@B71]; Tyurina et al., [@B91]). The pro-inflammatory, pro-oxidant milieu that develops in tissues in the aftermath of irradiation is therefore one that encourages immune recognition and that comes with the possibility of autoimmunity.

Historically, autoimmunity was considered to be an aberrant response. More recently, it has been recognized as a normal condition with cells with potential self-reactivity existing in everyone, even though autoimmune disease *per se* is relatively uncommon, afflicting 5--8% of the population in the USA. The question is whether radiation treatment generates anti-self reactive responses, what types of response are generated, and whether they play a role in normal tissue effects. Unfortunately such responses are easy to observe only when they cause disease, which involves a degree of genetic susceptibility though this is not as important as environmental factors. Autoimmune disease after radiation therapy may, however, develop more readily in people with a family history of autoimmunity and radiation may have a more detrimental effect in such a subpopulation. A case in point is the possible link between autoimmune celiac disease and susceptibility to radiation pneumonitis that seems to exist (Eriksen et al., [@B21]). In all these discussions, the extent of the radiation field and dose are important considerations for how irradiation alters the balance within the immune system and how it may drive autoimmune recognition.

The literature on radiation and autoimmunity is quite extensive. Mice prone to autoimmune thyroiditis respond to whole-body irradiation (WBI) with a higher incidence and higher severity of the disease and higher anti-thyroglobulin autoantibody titers than the wild type (Nagayama et al., [@B60]). Humans whose thyroids are exposed to radiation in therapeutic and environmental settings also develop elevated autoantibodies at least for a window of time (Brent, [@B10]). Other examples of radiation-induced autoimmunity exist. Morphea, a rare but painful skin complication in women following breast cancer radiotherapy may be in fact due to radiation-induced neoantigen formation (Laetsch et al., [@B39]). In a study of sialadenitis of the submaxillary gland in head and neck cancer patients following radiation therapy, it was concluded that acinar cell destruction was associated with an influx of cytotoxic T cells (Teymoortash et al., [@B86]). In the lung, lymphocytic alveolitis is a marker of radiation pneumonitis in breast cancer patients receiving radiation therapy (Toma et al., [@B88]) and T cells can readily be isolated from bronchoalveolar lavage in patients after lung irradiation (Nakayama et al., [@B62]). Even radiation doses that do not cause any obvious lung damage can elevate T cell numbers in bronchoalveolar lavage fluids in mice for a long time (Johnston et al., [@B34]). It is not surprising that radiation-induced interstitial pneumonitis and alveolitis is a common complication in syngeneic and allogeneic bone marrow transplantation (Shankar et al., [@B81]; Beyzadeoglu et al., [@B8]) and that this can be exacerbated by T cell responses to infectious agents (Bruckner et al., [@B11]). Cyclophosphamide given in combination with WBI also increases the damage to the lung and there is an inverse relationship with bone marrow damage (Yan et al., [@B99]). This reciprocal relationship might in part be because some of the radiation-induced lung damage is in fact immune-mediated, i.e., it needs the supply of immune players from the bone marrow. In keeping with this concept, thymic reprocessing seemed to enhance the incidence of radiation-induced pneumonitis in mice as it was decreased by thymectomy of mice receiving WBI and syngeneic bone marrow transplantation; an effect that was reversed by spleen cell delivery (McBride and Vegesna, [@B53], [@B54]). The ability of radiation to cause autoimmunity was emphasized by the finding that very high-dose, fractionated, total lymphoid irradiation (TLI)-induced multi-organ autoimmunity in mice, with characteristics dependent on radiation dose, extent of lymphoid irradiation, and the genetic background (Sakaguchi et al., [@B73]). This contrasts with studies where irradiation has been used to suppress autoimmunity.

Suppression of autoimmunity after tissue irradiation
====================================================

Despite the examples of radiation-induced autoimmune reactions cited above, remarkably, WBI or TLI followed by autologous stem cell transplantation has been used to treat already-established spontaneous autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis with the aim of eliminating autoreactive lymphocytes (Loor et al., [@B41]). Astonishingly, this is successful in a high proportion of patients despite the fact that depletion of autoreactive cells is never complete and there is always a possible contribution to failure from T cells in the autologous graft. Homeostatic expansion of Tregs may contribute but success seems to be mostly due to thymic-dependent regeneration of Tregs and reprogramming of the imbalanced immune networks following irradiation (van Wijk et al., [@B93]). This may take 9 months to occur in humans and there appears to be a window of time when tolerance can be re-established, with ongoing chronic inflammation and high levels of danger signaling being negative long-term predictors for success. In mice, low repeated doses of WBI attenuated autoimmune allergic encephalitis by up-regulating Tregs and suppressing IL-17 production (Tsukimoto et al., [@B90]), and appears to require recognition of TNFR2 on non-hematopoietic cells by Tregs (Tsakiri et al., [@B89]).

Similar immunosuppressive reprogramming can follow TLI. This was introduced in the late 1970s by Kaplan and Strober and later shown to be due to the generation of suppressor cells (Waer et al., [@B94]). Even patients with graft failure or graft rejection after allogeneic hematopoietic stem cell transplantation can be rescued by TLI-based reconditioning regimens resulting in sustained engraftment (Heinzelmann et al., [@B26]). The suppressor cells in the early preclinical studies of LTI and WBI were induced independent of the thymus (Weigensberg et al., [@B96]) and may have been myeloid or NKT cells, although the addition of anti-thymocyte serum to LTI has more recently documented Treg cell involvement (Nador et al., [@B59]). The explanation for the apparent discrepancy in radiation both causing and treating autoimmunity may lie in whether generalized immune reprogramming is occurring, whether the irradiation is localized or extensive, the radiation dose, the state of the immune system at the time of the exposure, i.e., in suppressor or effector mode, and the extent and nature of the "danger" signals that are generated. The immune system is normally in balance and this can be tipped in more than one direction depending on the therapeutic intervention. This will also change with time as different subsets take different times to regenerate. "Rebalancing" of course means something rather different if one is treating autoimmune disease as compared with cancer treatment or after a radiological incident. The important issue for the future is understanding the pathways involved so that they can be manipulated appropriately for the given situation.

Radiation kills lymphocytes selectively
=======================================

Radiation is often viewed as an immune-suppressive agent and most lymphocytes are indeed very radiation sensitive. Even local RT will have a direct cytotoxic effect on the circulating immunocyte pool as blood flows through the field, irrespective of other, more complex effects associated with immune activation. The extent of immune depletion will vary with the tissue, the size of the field, the delivery schedule, and dose (MacLennan and Kay, [@B46]). Cranial irradiation, for instance, can cause long-term lymphopenia in children to an extent that depends on the number of fractions i.e., dose (MacLennan and Kay, [@B46]). In reality, however, lymphocyte subsets differ in their radiation sensitivities. This is most obvious in lethal irradiation for bone marrow preconditioning, which does not eliminate all lymphocytes equally (Bagley et al., [@B4]). In very general terms, a spectrum of radiosensitivity exists from B cells through naive Th cells, NK cells, toward more radioresistant T memory cells (Belka et al., [@B7]) and NKT cells (Yao et al., [@B100]), and Tregs (Kachikwu et al., [@B36]). There is a tendency toward apoptosis denoting a more radiosensitive phenotype, while non-proliferative cells and activated lymphocytes are more radioresistant (McBride et al., [@B52]), although Tregs probably gain in radiosensitivity when they are induced (Awwad and North, [@B3]).

The end result is that irradiation imbalances the immune system. This may be restored with time depending upon the recovery time for the different immune subsets, but may also persist for long periods or even forever as is seen in A-bomb survivors. Since the distribution of T cell subsets is organ-specific (Matzinger and Kamala, [@B51]), recovery will proceed at different rates in different tissues and will depend on the chemokines produced (Pelus and Fukuda, [@B65]). An extreme example of this is recovery of γδTCR CD4+ intraepithelial T cells in the gut after WBI. This is independent of the thymus and occurs very rapidly in mice, while αβTCR T cells subsets take several weeks to recover (Mosley and Klein, [@B58]). In this analysis, the relative radiosensitivity and recovery of Tregs following local RT and WBI would be expected to be rapid if this mechanism protects against radiation-induced normal tissue damage.

Tregs and normal tissue radiation responses
===========================================

Recently, Tregs have been shown to be relatively radioresistant and their representation increases rapidly following irradiation, as might be expected if they are involved in limiting damage and associated inflammation (Cao et al., [@B14]; Kusunoki et al., [@B38]; Nakatsukasa et al., [@B61]; Qu et al., [@B69]; Weng et al., [@B97]; Billiard et al., [@B9]; Kachikwu et al., [@B36]). Further induction and activation may be through the powerful immune-suppressive cytokine TGF-β (Chen et al., [@B15]; Beal et al., [@B6]; Takahashi et al., [@B85]) that is induced by RT (Martin et al., [@B48]), but additional mechanisms are possible. We have shown radiation-enhanced expression of the ectonucleotidase CD39 on the Treg population (Schaue, unpublished), that was previously observed in cancer patients receiving RT (Mandapathil et al., [@B47]). Nucleotide catabolism by CD39 and CD73 with production of adenosine is probably [the]{.ul} most primitive immunosuppressive response to "danger." Adenosine has long been known to play a critical, non-redundant role in the protection of normal tissues from collateral damage during inflammation (Cronstein, [@B17]), including radiation-induced tissue damage (Hosek et al., [@B30]; Pospisil et al., [@B67], [@B68]; Hou et al., [@B31]), where it plays a protective role (Hofer et al., [@B28]). Support for this scenario comes from the observation that tissue derived adenosine acting through its receptor A~2A~R drives Tregs and limits autoimmune tissue destruction (Zarek et al., [@B102]).

Importantly, Treg radiosensitivity seems to depend upon their subtype and proliferative/activation status. This would explain the discrepancy seen between recent findings of radio-resistant Tregs and the radiation-sensitive Tregs first reported over 30 years ago (Hellstrom et al., [@B27]; Tilkin et al., [@B87]; North, [@B63]). Then, sublethal, WBI was used to eliminate suppressor T cells and uncover immune-mediated mechanisms leading to tumor regression. The timing of the radiation exposure post-tumor implantation was critical suggesting that a Treg subpopulation had been induced that was sensitive to radiation. Although Tregs have a reputation for being relatively anergic to antigenic stimulation *in vitro*, they appear to be able to proliferate *in vivo* following stimulation (Walker, [@B95]), which might make them radiosensitive. The type of Treg may also be important. The majority of Tregs are naturally occurring nTregs that come from the thymus. Induced Tregs can arise outside the thymus from peripheral conversion of CD4^+^CD25^−^ naïve T cells. Induction can be a result of exposure to low doses of antigen, IL-2, and TGF-β (Apostolou and von Boehmer, [@B2]; Curotto de Lafaille et al., [@B19]). So far it has remained difficult to definitively distinguish nTregs from iTregs, phenotypically and functionally, but it is clear that they do not have the same workload when it comes to controlling adaptive immune responses. There is some evidence that iTregs exert control of inflammatory responses at normal mucosal surfaces while nTregs appear more important for mediating self tolerance and tumor immune escape (Sakaguchi, [@B74], [@B75]; Curotto de Lafaille and Lafaille, [@B18]; Haribhai et al., [@B25]; Rosenblum et al., [@B72]; Josefowicz et al., [@B35]). The differential sensitivity of nTregs and iTregs and their proliferative versus non-proliferative state could go a long way toward explaining some of the divergent data emanating from studies on the effects of RT on autoimmunity and anti-tumor responses that are described above, although further studies are urgently needed to elucidate the critical variables in these systems.

Taken together, the idea that radiation drives Tregs to protect tissues against radiation damage seems plausible. Recent findings that Tregs regulate the hematopoietic stem cell niche (Urbieta et al., [@B92]) suggest an even more important role for these cells in maintaining microenvironments that are protected from pro-inflammatory influences and allowing them to regenerate after irradiation. The impairment in Tregs in acquired aplastic anemia is in keeping with this concept (Shi et al., [@B82]). At the same time, the ability of HIF-1α to drive Th17 cells toward differentiation and pro-inflammatory autoimmune responses (Pan et al., [@B64]), as can IL-6 and adenosine (Wilson et al., [@B98]), suggests ways in which the tissue microenvironment that is generated by irradiation might negate the influence of Tregs (Radhakrishnan et al., [@B70]). Other cytokines such as TGF-β, IL-1, IL-23, and TNF-α will also influence these processes (Schaue et al., [@B79]). The concept seems to be evolving that the balance between the normal tissue microenvironment induced by irradiation and the immune system is decisive in controlling the extent of damage and regeneration or replacement of tissue following exposure, and the degree of local immunity that is generated.

Intercepting immune mechanisms to protect normal tissues
========================================================

The picture that is emerging draws a line from radiation-induced tissue damage, the release of danger signals all the way to inflammation and the activation of the immune system and its immune control mechanisms, to tissue regeneration (Schaue and McBride, [@B78]). The immune cells that infiltrate the damaged area in the immediate aftermath of irradiation, as well as those cells that were affected directly during the radiation exposure will determine the ultimate fate of that tissue, with influence from the genetic make-up of the host and multiple tissue-specific factors. What is lacking is information regarding the extent of polarization within the T cell and other cellular compartments and the associated cytokines they release that we associate with various characteristic normal tissue side effects such as pneumonitis and fibrosis in the lung, demyelination, gliosis and vascular damage in the brain, erythema, desquamation, fibrosis in the skin, diarrhea, ulceration, and other intestinal dysfunctions (Brush et al., [@B12]; Linard et al., [@B40]; Schaue et al., [@B79]). Genetics will play a role as will standard radiobiological parameters of dose, dose rate, volume, etc. Defining the irradiated tissue microenvironment in these terms will be important if we wish to utilize the numerous tools that could be of value in radioprotecting normal tissues, mitigating radiation-induced damage, and treating patients with complications from RT. Tools to target pathways involving chemokines and cytokines like TNF-α, IL-1, CSFs, IL-6, IL-17, TGF-β, HIF-1, cell adhesion molecules, and receptors like ICAM-1, CD11b, TLRs, transcription factors like HIF-1, NF-κB, p53, STATs, as well as T cell subsets and immune modulatory molecules, are currently in the clinic or in the pipeline. Conceptually, the targets are fairly obvious, but target validation is generally poorly developed for radiation-induced normal tissue reactions. There are risks in trying to manipulate immune control mechanisms as was seen with TGN1412 (Hunig, [@B33]), however, the potential is great and the prize could be a major increase in radiotherapeutic benefit in cancer treatment and ways to improve the outcome of radiological accidents and incidents.
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